GlassScriptPhysician profile
Susan M Devers
NPI 1649598210
$3,159.78
in general payments reported to CMS, 2019-2025
27 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $180 · 2023: $405 · 2024: $664 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $367.55 | 2021-2025 | Confirm Rx, Merlin@Home, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $350.39 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $320.04 | 2022-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $289.84 | 2024-2025 | |
| Novo Nordisk INC | $264.68 | 2024-2025 | Ozempic, Wegovy |
| Pfizer INC. | $155.71 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $148.83 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.39 | 2025 | Jardiance |
| Cleerly, INC. | $123.27 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Abiomed | $122.86 | 2025 | |
| Alnylam Pharmaceuticals INC. | $118.99 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $116.15 | 2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $102.79 | 2025 | |
| Medtronic, INC. | $86.23 | 2025 | Linq II |
| Cvrx, INC. | $85.22 | 2024 | Barostim Neo System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $65.22 | 2023 | |
| Edwards Lifesciences Corporation | $61.36 | 2025 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $42.18 | 2025 | Attruby |
| Baxter Healthcare | $32.48 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $32.10 | 2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $31.57 | 2023 | Bodyguardian |
| Kiniksa Pharmaceuticals, LTD. | $30.13 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $17.67 | 2025 | |
| Esperion Therapeutics, INC. | $17.30 | 2025 | Nexletol |
| Ge Healthcare | $16.90 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Devers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.